Adam Lenkowsky, Executive Vice President, Chief Commercial Officer at Bristol Myers Squibb, shared on LinkedIn:
“Every day that a breakthrough therapy doesn’t reach the right patient is a day that matters.
One of the greatest opportunities in commercialization is closing the gap between insight and action – because faster, smarter decisions don’t just improve business outcomes. They can change lives.
Historically, teams have relied on lagging indicators, often course-correcting after critical windows have already passed. For patients living with serious diseases, that lag has real consequences.
In this article in The Wall Street Journal, Bristol Myers Squibb shares how we are working to change that with AI.
The result is sharper strategy, faster course corrections, and most importantly, a greater ability to ensure that the medicines we’ve worked so hard to develop reach the patients who need them most.
Because at the end of the day, our science only fulfills its promise when it gets to the people waiting for it.
I’m proud of the work our teams are doing to lead in this space.
Check out the full article here: Pharma’s Defining Moment in AI-Powered Commercialization.”
Other articles about AI and Bristol Myers Squibb on OncoDaily.